Is ipamorelin fda approved? the honest regulatory answer

Last updated 2026-07-25

is ipamorelin fda approved for any use?

No. There is no FDA-approved new drug application for ipamorelin, for any indication, in humans or animals. You can check this yourself in Drugs@FDA, the agency's public database of approved drug products ^[1]. Search "ipamorelin" and you get nothing, because nothing has cleared the approval pathway. That's a different question from whether ipamorelin has been studied. It has, pretty extensively, going back almost thirty years. The original characterization paper describing ipamorelin as "the first selective growth hormone secretagogue" ran in the European Journal of Endocrinology in 1998 ^[2]. Since then it has shown up in pharmacokinetic studies, animal models of bone growth and postoperative ileus, and more recent orthopedic and sports medicine literature ^[3][4]. Studied is not the same as approved. Lots of compounds get decades of academic attention without ever going through FDA review, usually because no company has run the Phase 3 trials and paid for a New Drug Application. Nobody has done that for ipamorelin. So the honest framing is: ipamorelin is a real, mechanistically characterized peptide with a real research record, and it is simultaneously an unapproved drug in the United States. Both things are true at once.

why hasn't ipamorelin gone through fda approval?

Mostly money and priorities, not a failed trial. Getting a peptide through FDA approval means Phase 1 through Phase 3 trials, manufacturing standardization, and a New Drug Application review, a process that easily runs into hundreds of millions of dollars and a decade or more. A company has to believe there's a commercial indication worth that investment. Ipamorelin's closest approved relative in spirit is tesamorelin, which did go through that process and is FDA-approved for HIV-associated lipodystrophy, marketed as Egrifta. Ipamorelin itself never had a sponsor take it that far. The 1998 medicinal chemistry work that produced ipamorelin was explicitly framed around finding "novel orally active growth hormone secretagogues" ^[5] and a related paper the same year described a series of "highly potent growth hormone-releasing peptides derived from ipamorelin" ^[6], so the early goal was clearly drug development. It just stalled before reaching a marketed product. A 2014 study did run ipamorelin through a real randomized controlled clinical trial for postoperative ileus after bowel resection, describing itself as a "prospective, randomized, controlled, proof-of-concept study" ^[7]. That's about as close as ipamorelin has come to a formal drug development track record in humans, and even that was proof-of-concept, not registration-grade.

if it's not approved, how is ipamorelin legally sold at all?

Through pharmacy compounding, which operates under a different legal framework than drug approval entirely. Compounding lets a licensed pharmacy prepare a customized medication for an individual patient based on a prescription, without that specific preparation going through its own NDA. The federal statute governing this is 21 U.S.C. 353a ^[8]. But compounding doesn't mean anything goes. The FDA maintains lists of bulk drug substances that compounders are allowed to use. For 503A pharmacies (traditional compounding pharmacies working from a patient-specific prescription), that's the 503A Bulks List under 21 CFR 216.23 ^[9]. For 503B outsourcing facilities (larger operations that can compound in bulk without a patient-specific script, under stricter cGMP oversight), the analogous list sits at 21 CFR 216.24 ^[10]. FDA also keeps a running list of substances nominated for 503A compounding that it's still evaluating ^[11]. This is the legal channel that lets ipamorelin reach patients in the US: a prescriber writes for it, a 503A or 503B pharmacy compounds it, and the pharmacy's compliance depends on the substance's status on those bulks lists and whether the prescription meets the requirements in 353a. It is not the same legal status as an FDA-approved drug, and it's worth being precise about that difference rather than blurring it.

is ipamorelin fda approved as a supplement instead?

No, and this one trips people up because "supplement" sounds like a lower bar. It isn't a separate legal shortcut here. Ipamorelin is a peptide intended to trigger a physiological hormone response, specifically growth hormone release through the ghrelin receptor pathway, which is squarely a drug function under FDA's own definition. Under 21 CFR 201.128, a product's "intended use" is determined by how it's marketed and what physiological effect it claims, and anything intended to affect the structure or function of the body in this way is regulated as a drug, not a dietary supplement ^[12]. So you'll sometimes see ipamorelin advertised as a "research chemical" or research-use-only product outside the compounding pharmacy channel. That's a separate, much shakier category with essentially no quality oversight. A 2018 analysis of black market growth-promoting products found real problems with mislabeling and purity in that space ^[13], which is exactly why the compounding pharmacy route, imperfect as it is, is the only channel with any pharmacy-level accountability attached to it.

what does the research actually say ipamorelin does?

Ipamorelin is a selective growth hormone secretagogue. That's the core finding from the 1998 European Journal of Endocrinology paper that first characterized it: it stimulates GH release through the ghrelin receptor pathway with, notably, minimal effect on cortisol, prolactin, or ACTH compared to older secretagogues, which was the whole point of calling it "selective" ^[2]. Animal studies have extended that picture. A 1999 study found ipamorelin "induces longitudinal bone growth in rats" ^[14]. A 2000 study in the Journal of Endocrinology found ipamorelin and GHRP-6 "increase bone mineral content in adult female rats" ^[15]. A 2001 study found ipamorelin "counteracts glucocorticoid-induced decrease in bone formation" in adult rats ^[16], which is relevant to anyone on long-term steroid therapy losing bone density. Human pharmacokinetic work from 1999 modeled dose-response relationships in volunteers ^[17], and a separate paper looked at nasal absorption pharmacokinetics ^[18]. There's also a distinct line of research on ipamorelin and gut motility. Multiple rodent studies found ipamorelin improves gastric dysmotility in models of postoperative ileus ^[19][20], which is what led to the human proof-of-concept ileus trial mentioned above ^[7]. None of this is bodybuilding-forum territory; it's mechanistic and clinical trial literature, published in real journals, and it's worth reading the actual papers rather than secondhand summaries.

is ipamorelin the same as cjc-1295, or fda approved together?

No to both. They're different molecules with different mechanisms, and neither is FDA-approved on its own. Ipamorelin is a ghrelin receptor agonist, a growth hormone secretagogue. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. They act on different receptors and are often combined precisely because they're complementary rather than redundant, one increases the amplitude of GH pulses and the other extends how long the pituitary stays responsive. That combination logic is also why ipamorelin rarely, if ever, appears in US compounding pharmacies as a standalone product. In practice it's dispensed as part of a tesamorelin/ipamorelin blend, since tesamorelin is the GHRH-analog component that has actual FDA approval history (as Egrifta, for HIV-associated lipodystrophy) and gives the compounded product a more defensible regulatory footing than an unapproved GHRH analog would. If you're comparing the ghrelin-mimetic route against an oral option, ibutamoren vs ipamorelin covers that mechanistic difference directly. Neither compound has run a Phase 3 program aimed at a registered indication in the US, so "FDA approved together" isn't a real category. What exists is compounded blends prescribed off a provider's clinical judgment, under the 503A/503B framework described above.

what other conditions has ipamorelin been studied for?

Beyond bone density and gut motility, there's a smaller but real body of work in other directions. A 2024 study in Physiology & Behavior found that ipamorelin, along with the related compound anamorelin, "inhibit cisplatin-induced weight loss in ferrets," with anamorelin also showing anti-emetic effects through a central mechanism ^[21]. This is chemotherapy-induced cachexia research, animal model, not a human oncology finding yet. A 2020 paper looked at ghrelin mimetics broadly and found effects on "attenuation of visceral and somatic nociception," meaning pain modulation in animal pain models ^[22]. A 2004 paper examined the "mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats" ^[23], suggesting effects beyond the GH axis alone. And a 2001 paper documented "GH-independent stimulation of adiposity by GH secretagogues" ^[24], a reminder that these compounds can have metabolic effects that don't run entirely through the growth hormone pathway, which matters for anyone assuming the whole effect profile is explained by GH and IGF-1 alone. More recent reviews, including a 2026 orthopedic peptide review ^[3] and a 2026 sports medicine peptide primer ^[4], place ipamorelin inside a broader wave of interest in therapeutic peptides for musculoskeletal and metabolic applications. A 2026 Sports Medicine review specifically addressed "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance" ^[25], which is a useful marker that the regulatory ambiguity around ipamorelin isn't unique to it. A lot of the peptide category sits in this same unapproved-but-studied zone.

how does ipamorelin's regulatory status compare to approved gh therapies?

This is where the gap is starkest. Recombinant human growth hormone (somatropin) has multiple FDA-approved products listed in Drugs@FDA for indications like adult growth hormone deficiency and pediatric growth failure ^[1]. Tesamorelin, the GHRH analog often paired with ipamorelin in compounded blends, is FDA-approved as Egrifta for HIV-associated lipodystrophy. Neither ipamorelin nor CJC-1295 has anything comparable.

does an unapproved status mean ipamorelin is unsafe?

Not automatically, but it does mean you don't get the safety net FDA approval provides. Unapproved doesn't equal dangerous, and approved doesn't equal risk-free either. What it means concretely is: no FDA-mandated post-market surveillance program, no standardized long-term safety trial data set at the scale required for approval, and quality control that depends entirely on which pharmacy compounded it. The existing safety signal from the literature is reassuring but limited. The original 1998 characterization found ipamorelin had minimal impact on cortisol and prolactin compared to other secretagogues ^[2], which is a favorable selectivity profile. Chronic treatment studies in young female rats looked at somatotroph (GH-secreting cell) responses after extended dosing ^[26]. But these are short studies, mostly animal or small human pharmacokinetic work, not the multi-year, multi-thousand-patient safety databases that come with full approval. A 2018 analysis of unregulated growth-promoting products found real quality problems in that space ^[13], which is a strong argument for sourcing only through a licensed 503A or 503B pharmacy under a provider's prescription, never from research-chemical vendors. That's also why proper technique matters: see ipamorelin how to inject and ipamorelin injection sites for the practical side of minimizing injection-related risk, and does ipamorelin need to be refrigerated for handling, since a mishandled peptide is a separate risk layer on top of the underlying regulatory gap.

where can you actually get ipamorelin legally in the us?

Through a prescriber and a compounding pharmacy, and only as part of a blend, not as a standalone ipamorelin product. Because there's no approved ipamorelin drug application, no retail pharmacy fills an "ipamorelin" prescription the way it would fill an approved medication. What exists instead is compounded preparations, most commonly a tesamorelin/ipamorelin blend, made by a 503A pharmacy against an individual prescription or by a 503B outsourcing facility under its own bulks list authorization ^[9][10]. Ipamorelin Co works with a provider-reviewed process that connects you to a licensed prescriber for evaluation and, where appropriate, a prescription fulfilled by a compounding pharmacy partner, rather than shipping a peptide with no medical oversight attached. That's a meaningfully different model from research-chemical websites, which sell peptides labeled "not for human consumption" specifically to sidestep the drug regulatory framework altogether, a workaround, not a legal channel. If you're trying to figure out whether ipamorelin fits your situation at all, the honest starting point is a conversation with a prescriber who can look at your labs and goals, not a forum thread. The regulatory status here is genuinely unresolved territory, not a settled "safe and approved" story, and any source telling you otherwise is skipping the CFR sections that actually govern this.

Frequently asked questions

is ipamorelin approved by the fda?

No. Ipamorelin has no FDA-approved New Drug Application and does not appear in the Drugs@FDA database. It is available in the US only through compounding pharmacies operating under 21 U.S.C. 353a, typically as part of a tesamorelin/ipamorelin blend, not as a standalone approved medication.

is ipamorelin legal to buy in the us?

It's legal to obtain through a prescription filled by a licensed 503A or 503B compounding pharmacy. It is not legal or safe to buy as an unregulated "research chemical" from online vendors, since those products bypass FDA oversight entirely and have shown real quality problems in independent testing.

why isn't ipamorelin fda approved if it has clinical studies?

Because being studied and being approved are different processes. FDA approval requires a sponsor to fund Phase 1 through Phase 3 trials and file a New Drug Application, a process costing hundreds of millions of dollars. Ipamorelin has real pharmacokinetic and animal data going back to 1998, but no company has taken it through full registration trials.

is ipamorelin a controlled substance?

Ipamorelin is not scheduled as a controlled substance under the Controlled Substances Act. Its legal status instead runs through FDA's compounding framework, meaning access depends on prescription requirements and bulk drug substance listing status under 21 CFR 216.23 and 216.24, not on narcotics scheduling.

is cjc-1295 fda approved either?

No. CJC-1295 is also an unapproved GHRH analog with no FDA-cleared drug application. Like ipamorelin, it reaches patients only through compounding pharmacies, and it's frequently combined with ipamorelin because the two act on different receptors (GHRH receptor versus ghrelin receptor).

can you buy ipamorelin alone, or only in a blend?

In practice, ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend rather than as a standalone SKU. Tesamorelin has its own FDA approval history as Egrifta, which gives the compounded blend firmer regulatory footing than an ipamorelin-only or ipamorelin/CJC-1295-only product would have.

is ipamorelin a supplement?

No. It doesn't qualify as a dietary supplement because it's intended to trigger a specific hormonal effect, growth hormone release, which under 21 CFR 201.128 makes it a drug by intended use regardless of how it's marketed. Any product sold as an ipamorelin "supplement" is misrepresenting its own regulatory category.

has ipamorelin been tested in humans?

Yes, in limited settings. A 1999 pharmacokinetic-pharmacodynamic study modeled dose-response in human volunteers, and a 2014 randomized controlled proof-of-concept trial tested ipamorelin for postoperative ileus after bowel resection. These are real human trials, but far short of the scale required for FDA approval.

what's the difference between fda approved and fda compliant compounding?

FDA approval means a specific drug product passed full agency review for safety and efficacy for a stated indication. Compounding compliance means a pharmacy is following the rules in 21 U.S.C. 353a and using substances on the applicable bulks list, a much lower bar that doesn't involve FDA reviewing the finished product itself.

is ipamorelin fda approved for weight loss or bodybuilding?

No, and it never had an intended-use application filed for either. The rat and ferret studies looking at fat and weight effects, including a 2001 paper on GH-independent adiposity stimulation, are preclinical animal research, not evidence supporting an approved weight-loss indication in humans.

does the fda regulate compounded ipamorelin blends at all?

Yes, but differently than approved drugs. 503A pharmacies and 503B outsourcing facilities operate under distinct FDA rules (21 CFR 216.23 and 216.24, plus 21 U.S.C. 353a) covering allowed substances and quality practices, but the finished compounded product itself never goes through FDA's premarket approval review.

where does ipamorelin's safety data come from if it's not fda approved?

Mostly animal studies (rats, ferrets, fish) and a handful of small human pharmacokinetic and proof-of-concept trials published in journals like the European Journal of Endocrinology and Pharmaceutical Research. It's real peer-reviewed science, but nowhere near the volume or scale of a full FDA safety review program.

Sources

1. FDA, Drugs@FDA database: Ipamorelin does not appear in the FDA's public database of approved drug products
2. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin was characterized as the first selective growth hormone secretagogue with minimal effect on cortisol and prolactin
3. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptide applications and challenges in orthopaedics, including growth hormone secretagogues
4. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer on injectable peptide therapy for orthopaedic and sports medicine physicians
5. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes the discovery of novel orally active growth hormone secretagogues including early ipamorelin-related chemistry
6. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Reports a series of highly potent growth hormone-releasing peptides derived from ipamorelin
7. International Journal of Colorectal Disease, 2014 (PMID 25331030): A prospective randomized controlled proof-of-concept trial tested ipamorelin for postoperative ileus after bowel resection
8. 21 U.S.C. 353a, pharmacy compounding: Sets the federal statutory framework allowing patient-specific pharmacy compounding of drugs like ipamorelin
9. 21 CFR 216.23, the 503A Bulks List: Lists bulk drug substances that 503A compounding pharmacies may use
10. 21 CFR 216.24, the 503B Bulks List: Lists bulk drug substances that 503B outsourcing facilities may use for bulk compounding
11. FDA, bulk drug substances nominated for use in compounding: FDA maintains a running list of substances nominated for 503A compounding still under evaluation
12. 21 CFR 201.128, meaning of intended uses: Defines that a product's intended physiological effect, not its marketing label, determines its regulation as a drug
13. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found quality and mislabeling problems
14. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats
15. Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
16. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats
17. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin was conducted in human volunteers
18. Xenobiotica, 1998 (PMID 9879640): Pharmacokinetic evaluation of ipamorelin included analysis of nasal absorption
19. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus
20. Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin showed efficacy in a rodent model of postoperative ileus
21. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin inhibited cisplatin-induced weight loss in ferrets
22. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics attenuated visceral and somatic nociception in animal pain models
23. Neuro Endocrinology Letters, 2004 (PMID 15665799): Examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats
24. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): Found GH-independent stimulation of adiposity by GH secretagogues
25. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Reviewed safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
26. Histology and Histopathology, 2002 (PMID 12168778): Studied somatotroph response after chronic ipamorelin treatment in young female rats